Pertussis epidemiology in Argentina: TRENDS after the introduction of maternal immunisation. Issue 7 (15th April 2018)

• Record Type: Journal Article
• Authors: Fabricius, G.; Martin Aispuro, P.; Bergero, P.; Bottero, D.; Gabrielli, M.; Hozbor, D.
• Is Part Of: Epidemiology and infection. Volume 146:Issue 7(2018)
• Page Start: 858
• Page End: 866
• Publication Date: 2018-04-15
• Subjects: Acellular vaccine, -- Bordetella pertussis, -- newborn's protection, -- pertussis, -- pregnancy immunisation; Communicable diseases -- Periodicals; Epidemiology -- Periodicals; 614.4
• DOI: 10.1017/S0950268818000808
• Languages: English
• ISSNs: 0950-2688

Abstract

Abstract: Data on the impact of the recently recommended maternal pertussis vaccination are promising, but still insufficient to universalise this approach. We thus compared the epidemiological data prior to the implementation of this vaccination strategy in Argentina (2012) with the figures reported after 2012. During that 2010–2016 period, two outbreaks occurred, one in 2011 and another in 2016. In the former, the incidence was 6.9/100 000 inhabitants and the case-fatality rate 2.6%. Thereafter, a decline in incidence was detected until 2014. During 2015 and 2016 an increase in the incidence transpired, but this rise was fortunately not accompanied by one in the case fatality ratio. Indeed, in 2016 the case fatality ratio was the lowest (0.6%). Moreover, during the 2016 outbreak, the incidence (3.9/100 000 inhabitants) and the case severity detected in the most vulnerable population (infants 0–2 months) were both lower than those in 2011. Consistent with this pattern, in 2016, in the most populated province of Argentina (Buenos Aires), the case percentage with laboratory-positive results indicating a high number of symptoms (59.1% of the total cases) diminished compared with that detected in the 2011 outbreak without maternal immunisation (71.9%). Using the mathematical model of pertussis transmission we previously designed, we assessed the effect of vaccination during pregnancy on infant incidence. From comparisons between the epidemiological data made through calculations, emerged the possibility that vaccinating women during pregnancy would benefit the infants beyond age 2 months, specifically in the 2–12-month cohort.